Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Stock Market News For Jun 20, 2019
by Zacks Equity Research
Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
by Zacks Equity Research
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
Big Drugmakers That May Tread the M&A Path After Pfizer
by Kinjel Shah
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $43.08 in the latest trading session, marking a +0.45% move from the prior day.
Protalix (PLX) Completes Enrollment in Fabry Disease Study
by Zacks Equity Research
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
by Sweta Killa
Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.
Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio
by Zacks Equity Research
Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.
Company News For Jun 18, 2019
by Zacks Equity Research
Companies In The News Are: DISH,TMUS,S,ARRY,PFE,BID,BA
Big Ticket Mergers Are in Focus
by Zacks Equity Research
Big Ticket Mergers Are in Focus
"Merger Monday" Returns: Pfizer Buying Array, T-Mobile-Sprint on Ice?
by Mark Vickery
News on two major mergers in their respective industries are taking headlines, along with a fresh regional economic read.
Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout
by Swarup Gupta
The index traversed a volatile week, guided largely by trade-related developments.
Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti
by Zacks Equity Research
FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.
Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study
by Zacks Equity Research
Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.
Galapagos Ends Enrollment in Osteoarthritis Study Before Time
by Zacks Equity Research
Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.
Novartis Reports Data on Cosentyx for Psoriatic Arthritis
by Zacks Equity Research
Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $43.10, marking a +1.01% move from the previous day.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Boost Your Portfolio's Health With These 3 Big Drug Stocks
by Kinjel Shah
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Top Ranked Income Stocks to Buy for June 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 12th
TherapeuticsMD Enters Agreement to Market Drugs Outside US
by Zacks Equity Research
TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $42.76, marking a +0.66% move from the previous day.
Lilly's Emgality Gets FDA Approval for Cluster Headache
by Zacks Equity Research
Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
Zacks Market Edge Highlights: Pfizer, Vanguard S&P 500 ETF, Global X Social Media ETF, Kraneshares China Internet ETF and Microsoft
by Zacks Equity Research
Zacks Market Edge Highlights: Pfizer, Vanguard S&P 500 ETF, Global X Social Media ETF, Kraneshares China Internet ETF and Microsoft
Blueprint Medicines to File NDA for Avapritinib With FDA
by Zacks Equity Research
Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.
Top Tips for Long-Term Stock Investors
by Tracey Ryniec
The stock market is volatile again. Here's how to make it through the ups and downs.